NZ330758A - Treatment of neural damage using GPE (the tripeptide gly-pro-glu) - Google Patents

Treatment of neural damage using GPE (the tripeptide gly-pro-glu)

Info

Publication number
NZ330758A
NZ330758A NZ330758A NZ33075894A NZ330758A NZ 330758 A NZ330758 A NZ 330758A NZ 330758 A NZ330758 A NZ 330758A NZ 33075894 A NZ33075894 A NZ 33075894A NZ 330758 A NZ330758 A NZ 330758A
Authority
NZ
New Zealand
Prior art keywords
pro
glu
gpe
treatment
tripeptide gly
Prior art date
Application number
NZ330758A
Inventor
Peter David Gluckman
Christopher Edward Williams
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Priority to NZ330758A priority Critical patent/NZ330758A/en
Publication of NZ330758A publication Critical patent/NZ330758A/en

Links

Abstract

The specification describes the use of a peptide selected from the group: (a) the tripeptide gly-pro-glu (GPE); (b) the dipeptide gly-pro and (c) the dipeptide pro-glu in the manufacture of a medicament for preventing or inhibiting death of neural cells in a mammal and therefore to treat neurological disease or disorder.
NZ330758A 1993-12-23 1994-12-20 Treatment of neural damage using GPE (the tripeptide gly-pro-glu) NZ330758A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ330758A NZ330758A (en) 1993-12-23 1994-12-20 Treatment of neural damage using GPE (the tripeptide gly-pro-glu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ25057293 1993-12-23
NZ26009194 1994-03-14
NZ26407094 1994-07-22
NZ330758A NZ330758A (en) 1993-12-23 1994-12-20 Treatment of neural damage using GPE (the tripeptide gly-pro-glu)
NZ27789194 1994-12-20

Publications (1)

Publication Number Publication Date
NZ330758A true NZ330758A (en) 2000-05-26

Family

ID=27484332

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ330758A NZ330758A (en) 1993-12-23 1994-12-20 Treatment of neural damage using GPE (the tripeptide gly-pro-glu)

Country Status (1)

Country Link
NZ (1) NZ330758A (en)

Similar Documents

Publication Publication Date Title
ATE151293T1 (en) IGF-I TO IMPROVE THE NEURAL SITUATION
ES2140463T3 (en) PREVENTION AND TREATMENT OF PERIPHERAL NEUROPATHY.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
EP0923293A4 (en) Treatment of diarrhea
HK1058892A1 (en) The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith in protecting cns cells from glutamate toxicity
GEP19991515B (en) Pharmaceutical Composition
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
WO2000063246A3 (en) Compounds and methods for modulating beta-catenin mediated gene expression
EP0616032A3 (en) Preventive or therapeutic agents for Alzheimer's disease, a screening method for Alzheimer's disease, and human tau-protein kinase.
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
PL302304A1 (en) Peptides of body organs protecting action, method of obtaining them and their application in therapy
DE69333639D1 (en) Trypsininhibitoren
HU9502573D0 (en) Recombinant adenoviruses and use thereof in gene therapy
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
ES2176250T3 (en) PROTEIN ANTI RESTENOSIS.
NZ330758A (en) Treatment of neural damage using GPE (the tripeptide gly-pro-glu)
AU4762893A (en) Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
TW370461B (en) Use of cross-linked hemoglobin in treating subarachnoid hemorrhage
HUP9901659A3 (en) Use of flupirtin for producing pharmaceutical compositions suitable for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system
KR100488038B1 (en) New bpc peptide salts with organo-protective activity the process for their preparation and their use in therapy
WO1995007708A3 (en) Therapeutic use of the retinoblastoma susceptibility gene product
AU6251594A (en) Treatment of cancerous growths with biologically active peptides and protease inhibitors
NZ268039A (en) Use of efaroxan in treating parkinson's disease
EP0651816A4 (en) Blood levels of cck peptides relative to panic disorder treatment.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: NEUREN PHARMACEUTICALS LIMITED, NZ

Free format text: OLD OWNER(S): NEUREN PHARMACEUTICALS LIMITED; AUCKLAND UNISERVICES LIMITED

Owner name: NEUREN PHARMACEUTICALS LIMITED, NZ

Free format text: OLD OWNER(S): NEURONZ LIMITED

RENW Renewal (renewal fees accepted)
EXPY Patent expired